Improved Glycemic Control Through the Use of a Telehomecare Program in Patients with Diabetes Treated with Insulin.

With the drastic surge in the prevalence of diabetes, the use of medical resources for management of diabetic patients increased markedly. This study aimed to evaluate the impact of telehomecare (THC) use on clinical efficacy, nursing interventions, and medical visits compared with the standard care in insulin-treated diabetic patients. A prospective noninferiority clinical trial was designed. Participants were assigned to either an intervention group provided with a THC system during 3 months or to a control group. Main outcome was the difference in A1c at 3 months compared with baseline. Secondary outcomes were the difference in A1c at 6 months compared with baseline, the number of medical visits during the 6-month period of the study, and nursing interventions during the 3 months on THC. A total of 92 participants completed the study. A significant decrease in A1c levels was observed in the THC group ( = 45) compared with the control group ( = 47) at 3 months (-0.61% vs. -0.06%, respectively,  = 0.048) and at 6 months (-0.37% vs. -0.10%, respectively,  = 0.036). The THC group had an average of 0.6 medical visit compared with 1.0 in the control group ( < 0.001). An increase in nursing interventions (mainly e-mails) was noted in THC group ( = 14.7) compared with control group ( = 1.1). This THC program demonstrates improvement in glycemic control and a decrease in the number of medical visits. However, it is important to consider an additional burden in nursing interventions when implementing a THC program.